Ardais
Corporation
One Ledgemont Center
128 Spring Street
Lexington, MA 02421
T: 781-274-6420
F: 781-274-6421
Ardais, acquired by Gulfstream Bioinformatics Corporation in 2006, was recognized as a leading human tissue repository supporting genomics- and proteomics-based research. It supplied biorepository services to more than 50 major medical institutions and companies.
Ardais collaborated with the University of Pittsburgh Cancer Institute and the Pennsylvania Cancer Alliance Bioinformatics Consortium to demonstrate a National Biospecimen Network (NBN) pilot. The NBN is an initiative of the National Cancer Institute that will provide a national, standardized tissue resource openly accessible to cancer researchers across the country.
Lancet Capital initiated and led a PIPE investment in Dyax (NASDAQ: DYAX) in 2003.
Dyax is a biotechnology company focused on developing and commercializing drugs in the areas of inflammation and oncology. It has a revenue-generating drug discovery technology platform called “phage display” and its lead drug (DX-88) is currently in a Phase III clinical trial for treating a genetic disorder.
The University of Pittsburgh Medical Center is participating in the Phase III clinical trial of DX-88.
BioSafe, Inc.
100 Technology Drive, Suite 400
Pittsburgh, PA 15219
T: 412-201-7370
F: 412-770-1276
BioSafe, Inc. is a medical device company commercializing a unique polymer technology that offers long lasting protection from bacteria (e.g., pneumonia) and viruses (e.g., HIV) without promoting the emergence of microbes that are drug resistant. The technology has broad potential application in many consumer and medical product markets.
Enanta is a drug discovery company that morphs existing drugs, natural products and biologically-active peptide leads into small molecules with improved pharmacological properties. The Company initially concentrated its proprietary discovery efforts in two therapeutic areas: immunosuppressants and macrolide antibiotics.
Enanta, in collaboration with the University of Pittsburgh, discovered a new class of immunosuppressants. It has also discovered novel macrolide antibiotic compounds that overcome bacterial resistance and have improved biological profiles. Its lead macrolide drug (EP-420) is in a Phase II clinical trial for the treatment of community respiratory tract infections.
Scion
Pharmaceuticals
200 Boston Avenue
Suite 3600
Medford, MA 02155
T: 781-391-1900
F: 781-306-0880
Scion was acquired by Wyeth (NYSE: WYE) in 2005, having developed a unique library of ion channel compounds for treating pain. Animal data suggested that its lead pain drug candidate was potentially more efficacious than the leading neuropathic pain therapeutic.
Scion used an integrated strategy of functional genomics, chemistry and High-Throughput ElectroPhysiology (HTEP™) to discover ion channel drugs. HTEP™, licensed exclusively from Boston University, is a unique drug screening technology that permitted the rapid discovery and optimization of small molecule drugs that modulate ion channels.
Stemnion, co-founded and seeded by Lancet Capital, is developing a proprietary amnion-derived stem cell technology platform for wound healing and cellular therapy (e.g., diabetes). Stemnion is collaborating with highly distinguished advisors and scientists at the University of Pittsburgh, Cambridge University, University of Michigan and University of South Florida.
The company has rapidly advanced to the pre-clinical stage of drug development in wound healing and is a leader in differentiation of stem cells into islet-like cells. There is an urgent need for new and effective therapies for unmet wound management needs, and many also have military significance. Consequently, Stemnion has worked with various arms of the federal government to secure funding and cooperative partnerships.
Stentor was co-founded and seeded by Lancet Capital. It was acquired by Philips (NYSE: PHG) in 2005.
Stentor developed an enterprise-wide imaging and information solution for the healthcare industry and was the second largest supplier of Picture Archiving and Communication Systems (PACS) in the United States. Its technology was the first viable option for the dynamic real time transfer of high quality images across the healthcare enterprise using existing networks and standard PC's.
Stentor licensed its core technology from the University of Pittsburgh. It conducted beta testing at the University of Pittsburgh Medical Center, which was also a major customer.
VivoQuest was co-founded and seeded by Lancet Capital. It was acquired by XTL Biopharmaceuticals (NASDAQ: XTLB) in 2005.
VivoQuest was a drug discovery company with a breakthrough small molecule chemistry technology known as Diversity Oriented Synthesis (“DOS”) for the rapid discovery and development of small molecule drugs derived from natural products.
In collaboration with world class virologists at Rockefeller University, the Company used its proprietary compound libraries and DOS technology to develop a portfolio of small molecule drug leads for the treatment of hepatitis C.